About Us
The Buchholz Lab
Systems biology and genome engineering are at the forefront of transforming our healthcare system. The Department of Medical Systems Biology at the University Cancer Center of TU Dresden integrates functional genomics, high-throughput biology and genome editing to transform precision medicine. Join us in shaping the future of healthcare science!
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Prof. Dr. Frank Buchholz
Frank is passionate about the development and application of functional genomics and genome engineering in biomedical science. He was one of the first scientists to perform genome-scale RNAi screens in human cells, and has pioneered genome surgery as a disruptive new biotechnology. Frank has also been a strong leader in industrial innovation and co-founded several biotechnology companies.
Research
Find out more about our research
Publications
Follow the work of our researchers
Members
Your contact to our research group members
News
Get to know the news of our research group
News
Frank Buchholz honoured for his commitment to transfer innovation from research to industry
6. September 2023
On 6 September 2023, UNIPRENEURS honoured 20 outstanding professors & founders for their achievements in transfer of innovation who had been selected from 700 nominations. Prof. Dr. Frank…
Frank Buchholz and Seamless Therapeutics GmbH on designer recombinases competing with CRISPR
1. September 2023
In our latest news release, Frank Buchholz (TU Dresden) and Anne-Kristin Heninger (Seamless Therapeutics GmbH) look at how designer recombinases have become a strong competitor of CRISPR. Explaining…
Laborjournal on Seamless Therapeutics
30. June 2023
In their news article in Laborjournal, the Dresden-based start-up Seamless Therapeutics reflects on programmable recombinases that operate independently of the cell's own DNA repair system and could…